ProQR Therapeutics NV
PRQR2.125USD
+0.045+2.16%
Market hours （ET）Quotes delayed by 15 min
228.89MMarket Cap
LossP/E TTM
More Details of ProQR Therapeutics NV Company
ProQR Therapeutics N.V. is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010, an RNA-based oligonucleotide for the treatment of cystic fibrosis (CF), QR-110, an oligonucleotide and for the treatment of Leber’s congenital amaurosis (LCA).
Company Info
Ticker SymbolPRQR
Company nameProQR Therapeutics NV
IPO dateSep 18, 2014
CEOMr. Daniel Anton de Boer
Number of employees166
Security typeOrdinary Share
Fiscal year-endSep 18
AddressZernikedreef 9
CityLEIDEN
Stock exchangeNASDAQ Capital Market Consolidated
CountryNetherlands
Postal code2333 CK
Phone31881667000
Websitehttps://www.proqr.com/
Ticker SymbolPRQR
IPO dateSep 18, 2014
CEOMr. Daniel Anton de Boer
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Gerard Platenburg, Ph.D.
Mr. Gerard Platenburg, Ph.D.
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
824.39K
--
Mr. Dinko Valerio, Ph.D.
Mr. Dinko Valerio, Ph.D.
Non-Executive Director
Non-Executive Director
725.69K
--
Dr. James Samuel Shannon, M.D.
Dr. James Samuel Shannon, M.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
61.54K
--
Mr. Daniel Anton de Boer
Mr. Daniel Anton de Boer
Chief Executive Officer, Founder, Executive Director
Chief Executive Officer, Founder, Executive Director
--
-100.00%
Dr. Martin Maier, Ph.D.
Dr. Martin Maier, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Sheila Sponselee
Ms. Sheila Sponselee
Chief People and Operations Officer
Chief People and Operations Officer
--
--
Mr. Bart Filius
Mr. Bart Filius
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Begona Carreno, Ph.D.
Ms. Begona Carreno, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Theresa M. Heggie
Ms. Theresa M. Heggie
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Alison F. Lawton
Ms. Alison F. Lawton
Non-Executive Independent Director
Non-Executive Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Gerard Platenburg, Ph.D.
Mr. Gerard Platenburg, Ph.D.
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
824.39K
--
Mr. Dinko Valerio, Ph.D.
Mr. Dinko Valerio, Ph.D.
Non-Executive Director
Non-Executive Director
725.69K
--
Dr. James Samuel Shannon, M.D.
Dr. James Samuel Shannon, M.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
61.54K
--
Mr. Daniel Anton de Boer
Mr. Daniel Anton de Boer
Chief Executive Officer, Founder, Executive Director
Chief Executive Officer, Founder, Executive Director
--
-100.00%
Dr. Martin Maier, Ph.D.
Dr. Martin Maier, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Sheila Sponselee
Ms. Sheila Sponselee
Chief People and Operations Officer
Chief People and Operations Officer
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, May 17
Updated: Sat, May 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Eli Lilly and Company
16.06%
Van Herk Investments
10.93%
Adage Capital Management, L.P.
7.70%
Privium Fund Management BV
4.75%
Affinity Asset Advisors LLC
3.12%
Other
57.44%
Shareholders
Shareholders
Proportion
Eli Lilly and Company
16.06%
Van Herk Investments
10.93%
Adage Capital Management, L.P.
7.70%
Privium Fund Management BV
4.75%
Affinity Asset Advisors LLC
3.12%
Other
57.44%
Shareholder Types
Shareholders
Proportion
Hedge Fund
21.84%
Corporation
16.06%
Investment Advisor
11.42%
Family Office
10.93%
Investment Advisor/Hedge Fund
4.91%
Individual Investor
2.00%
Research Firm
1.72%
Bank and Trust
0.04%
Venture Capital
0.02%
Other
31.06%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
122
61.04M
58.02%
-5.87M
2025Q1
131
62.09M
59.01%
-3.97M
2024Q4
135
61.46M
58.04%
+24.32M
2024Q3
126
39.02M
42.64%
-5.37M
2024Q2
127
38.86M
42.67%
-6.74M
2024Q1
137
38.95M
43.54%
-15.29M
2023Q4
162
39.95M
44.78%
-23.51M
2023Q3
167
40.45M
49.96%
-14.58M
2023Q2
170
45.68M
56.49%
-13.40M
2023Q1
180
47.05M
58.19%
-9.38M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Eli Lilly and Company
16.90M
16.06%
+3.52M
+26.35%
Dec 31, 2024
Van Herk Investments
11.50M
10.93%
+40.00K
+0.35%
May 23, 2025
Adage Capital Management, L.P.
8.10M
7.7%
-1.50M
-15.62%
Mar 31, 2025
Privium Fund Management BV
4.99M
4.74%
--
--
Mar 31, 2025
Affinity Asset Advisors LLC
3.28M
3.12%
+459.51K
+16.27%
Mar 31, 2025
Millennium Management LLC
2.07M
1.97%
-756.63K
-26.76%
Mar 31, 2025
Sio Capital Management, LLC
2.05M
1.95%
--
--
Mar 31, 2025
abrdn Inc.
1.85M
1.76%
+1.85M
--
Mar 31, 2025
UBS Financial Services, Inc.
1.78M
1.69%
-511.49K
-22.30%
Mar 31, 2025
Kynam Capital Management LP
1.75M
1.66%
--
--
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
Avantis International Small Cap Value ETF
0%
Invesco NASDAQ Future Gen 200 ETF
0%
Avantis International Small Cap Equity ETF
0%
Avantis International Small Cap Value ETF
Proportion0%
Invesco NASDAQ Future Gen 200 ETF
Proportion0%
Avantis International Small Cap Equity ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
